

of the molecular weight markers to make it appear more consistent with the expected experimental results. Dr. Jacoby then submitted the plagiarized and falsified results to a MGH colleague who included them in a presentation at the First Annual Meeting of the American Society of Gene Therapy, held in Seattle, Washington, on May 30, 1998.

During the institutional investigation in 1998, Dr. Jacoby presented another falsified image as data from his own experiment. Specifically, he used computer software to scan Figure 3A in Balagué et al. and then alter the locations of three major bands in an effort to conceal the origin of the falsified image (i.e., Figure 3A) and to deceive investigating officials into believing that the results were from an independent experiment. Dr. Jacoby then used the different band locations as "evidence" of the differences between Figure 3A by Balagué et al. and the data purportedly from his own experiment by presenting the falsified image: (1) To the Chief of MGH's Neurology Service; (2) to a scientist assisting the Inquiry Committee by attempting to reproduce Dr. Jacoby's experiment; and (3) to the Inquiry Committee as data from his own independent experiment.

After the institution concluded that Dr. Jacoby had engaged in scientific misconduct, Dr. Jacoby forged the signature of the institutional official for the MGH Grants and Contracts Office and knowingly included false and material information on his NIH non-competing renewal application for a Clinical Investigator Award, 5 K08 NS01887-05. Specifically, after ceasing to work in his supervisor's laboratory and after being told by his supervisor that she would no longer serve as his mentor on the Clinical Investigator Award, Dr. Jacoby (1) listed his former supervisor as his mentor on his 5 K08 NS01887-05 application; (2) claimed that he was continuing to conduct grant-funded research in her laboratory; (3) forged the signature of the MGH institutional official to avoid detection by MGH; and then (4) submitted the completed application directly to NIH on or about August 1, 2000.

Dr. Jacoby's actions amount to significant and serious falsifications in the proposing and reporting of research. His falsifications gave NIH reviewers inaccurate information for their evaluation of the progress made by the research group at MGH in its PHS-supported research. His falsifications also substantially hindered the progress of the PHS-funded research project. Finally, his falsifications induced NIH to conditionally approve Dr. Jacoby's 5

K08 NS01887-05 grant at a time when he was no longer conducting research.

Accordingly, PHS further finds that Dr. Jacoby engaged in a pattern of dishonest conduct through the commission of 15 acts of data falsification and plagiarism, including additional steps taken to conceal the true nature and origin of the research data, that further demonstrates a lack of present responsibility to be a steward of Federal funds.

Dr. Jacoby has entered into a Voluntary Exclusion Agreement with PHS in which he has voluntarily agreed for a period of five (5) years, beginning on June 12, 2001:

(1) To exclude himself from any contracting or subcontracting with any agency of the United States Government and from eligibility for, or involvement in, nonprocurement transactions (e.g., grants and cooperative agreements) of the United States Government as defined in 45 C.F.R. Part 76 (Debarment Regulations);

(2) To exclude himself from serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative Oversight, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852, (301) 443-5330.

Chris B. Pascal,

Director, Office of Research Integrity.

[FR Doc. 01-17150 Filed 7-9-01; 8:45 am]

BILLING CODE 4150-31-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration on Aging

Agency Information Collection Activities: Proposed Submission to the Office of Management and Budget (OMB) for Clearance; Comment Request; Reinstatement of a Previously Approved Information Collection

AGENCY: Administration on Aging, HHS.

The Administration on Aging (AoA), Department of Health and Human Services, provides an opportunity for comment on the following proposal for the collection of information in compliance with the Paperwork Reduction Act (PRA; Public Law 96-511):

Title of Information Collection: Grantee Data Collection for the Evaluation of the Alzheimer's Disease Demonstration Grants to States Program.

Type of Request: Reinstatement of a previously approved collection for which approval has expired. This request significantly streamlines and reduces the amount of data collected as compared to previously approved requirements.

Use: Data is collected on client demographic and health characteristics, client service use, and program characteristics to adequately evaluate the implementation, progress and process of the Alzheimer's Disease Demonstration Grants to States Program (Section 398 of the Public Health Service Act, Pub. L. 78-410 as amended). Data is used by the grantee states to manage and evaluate their own programs. The data is also used by the AoA to evaluate and describe all projects funded by this initiative and address the program's statutory evaluation and Government Performance and Results Act (GPRA) requirements. Findings are used to manage the program and better target future activities, as well as to provide a final evaluation of each set of grants to Congress as set forth by statute.

Frequency: Client Intake Form—only once per client, data submitted quarterly, Service Use Form—quarterly, Agency Service Profile Form—annually.

Respondents: Agencies of State Governments and Territories that have been designated by the Governor as the sole applicant for the State and who have applied for a grant under this program.

Estimated Number of Responses: Client Intake Form—5000/year, Service Use Form—2500/year, Agency Service Profile Form—125/year.

Total Estimated Burden Hours: Client Intake Form—100 hours/state/year, Service Use Form—420 hours/state/year, Agency Service Profile Form—1.25 hours/state/year.

Additional Information or Comments: The Administration on Aging plans to submit to the Office of Management and Budget for reinstatement of a previously approved collection for which approval has expired, for the Alzheimer's Disease Demonstration Grants to States Program, pursuant to requirements set forth by statute. Written comments and recommendations for the proposed information collection should be sent within 60 days of the publication of this notice directly to the following address: Office of Program Development, Administration on Aging, Attention: Melanie Starns, 330 Independence Avenue, SW., Rm. 4270, Washington, DC 20201.

Dated: July 3, 2001.

Norman L. Thompson,

*Acting Principal Deputy Assistant Secretary
for Aging.*

[FR Doc. 01-17116 Filed 7-9-01; 8:45 am]

BILLING CODE 4154-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Embargo on Importation of *Dracaena* Shipments in Standing Water

AGENCY: Centers for Disease Control and
Prevention (CDC), HHS.

ACTION: Notice of embargo on
importation of *Dracaena* shipments in
standing water.

SUMMARY: Shipments of *Dracaena*
("lucky bamboo") in standing water and
infested with mosquitoes are currently
being imported into the United States.
Because of potential public health
threats posed by exotic species of
mosquitoes, CDC is implementing an
immediate embargo on the importation
of *Dracaena* that has been shipped in
standing water. This embargo only
affects importation of *Dracaena*
shipments in standing water.

FOR FURTHER INFORMATION CONTACT: Dr.
David Kim, Centers for Disease Control
and Prevention, 1600 Clifton Road, NE.,
National Center for Infectious Diseases,
Division of Global Migration and
Quarantine, Mailstop E-03, Atlanta,
Georgia, 30333; (404) 498-1600; E-mail
ddk5@cdc.gov.

SUPPLEMENTARY INFORMATION:

Background

On June 14, 2001, the Centers for
Disease Control and Prevention (CDC),
was notified by the Los Angeles district
office of the U.S. Department of
Agriculture (USDA) that it had
identified maritime cargo containers of
"lucky bamboo" (*Dracaena* species), an
ornamental plant, that were infested
with mosquitoes. CDC subsequently
identified the Asian tiger mosquito,
Aedes albopictus, a species previously
not seen in California, and other species
of mosquitoes associated with these
cargo containers. The *Dracaena* in the
infested cargo containers was shipped
in small boxes with two to three inches
of standing water. Shipments of
Dracaena with no standing water or
associated mosquito infestation have
been arriving in the United States from
China, Taiwan, Thailand, Indonesia,
Malaysia, Costa Rica and other countries

as air and maritime cargo for at least 3
years.

Public Health Risks

Dracaena shipments in standing
water appears to pose a considerable
risk of importing exotic mosquitoes into
the United States. Although previously
introduced and widely established in
the eastern half of the United States,
Aedes albopictus has not established a
population in California. *Aedes*
albopictus is capable of transmitting
serious human diseases such as western
equine encephalitis, St. Louis
encephalitis, and dengue viruses.
Introduction of new *Aedes albopictus*
populations from China, Taiwan,
Indonesia, and other countries might
include genotypes that are more
efficient vectors of human diseases than
the genotypes that are currently present
in the United States. There have been
precedents of accidental introduction of
mosquito species of public health
importance into the United States by a
similar mechanism, i.e., by importation
of materials containing standing water.

Immediate Action

Introductions of exotic species of
mosquitoes, such as *Aedes albopictus* in
California and other species in different
parts of the United States, through the
importation of *Dracaena* shipments in
standing water, pose potentially serious
public health threats. Accordingly,
pursuant to 42 CFR 71.32(c), CDC is
implementing an embargo on the
importation of *Dracaena* shipments in
standing water, effective immediately.
This embargo only affects importation of
Dracaena shipments in standing water.

Dated: July 3, 2001.

Joseph R. Carter,

*Associate Director for Management and
Operations, Centers for Disease Control and
Prevention.*

[FR Doc. 01-17152 Filed 7-9-01; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Program Announcement 01098]

Well-Integrated Screening and Evaluation for Women Across the Nation (WISEWOMAN); Notice of Availability of Funds

A. Purpose

The Centers for Disease Control and
Prevention (CDC) announces the
availability of fiscal year (FY) 2001

funds for a cooperative agreement
program for Well-Integrated Screening
and Evaluation for Women Across the
Nation (WISEWOMAN). This program
addresses the "Healthy People 2010"
focus areas of Nutrition and Overweight,
Physical Activity and Fitness, Tobacco
Use, Heart Disease and Stroke, Diabetes,
and Access to Quality Health Services.

The purpose of this program is to use
scientifically rigorous methods to test
the effectiveness of a behavioral or
lifestyle intervention aimed at
preventing cardiovascular disease (CVD)
and other chronic diseases. The target
population consists of women
participating in the National Breast and
Cervical Cancer Early Detection Program
(NBCCEDP). The major long-term goal is
to demonstrate a successful behavioral
or lifestyle intervention for the
population targeted by the NBCCEDP.
Recipients are also expected to work
with existing health care systems to
identify free or discounted medication
for women who require such therapy.

B. Eligible Applicants

Assistance will be provided only to
the health departments of States or their
bona fide agents, including the District
of Columbia, the Commonwealth of
Puerto Rico, the Virgin Islands, the
Commonwealth of the Northern Mariana
Islands, American Samoa, Guam,
federally recognized Indian tribal
governments, the Federated States of
Micronesia, the Republic of the
Marshall Islands, and the Republic of
Palau. NBCCEDP grantees who are
currently receiving grants under
Program Announcements 99135 and
00115 are not eligible.

C. Availability of Funds

Approximately \$2,000,000 is available
in FY 2001 to fund two awards. It is
expected that the average amount per
award is between \$750,000 to
\$1,250,000. It is expected that the
awards will begin on or about
September 30, 2001, and will be made
for a 12-month budget period within a
project period of three years. Funding
estimates may change.

Continuation awards within an
approved project period will be made
on the basis of satisfactory progress as
evidenced by required reports and the
availability of funds.

1. Use of Funds

In accordance with Public Law 101-
354, an award may not be made unless
the State/Territory/Tribe involved
agrees that:

a. At least 60 percent of cooperative
agreement funds will be expended for
screening, lifestyle intervention, public